anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: Volvulus is a disease characterized by the abnormal twisting of a gaseous distension of the loop of the intestine around itself. Colonic volvulus is the third common cause of colonic obstruction. The study aimed to determine whether the percentage of immature granulocytes is a marker of early necrosis in the volvulus.
METHODS: Demographic characteristics of the cases were collected in the study. In addition, age, gender, white blood cell count, immature granulocyte count, immature granulocyte percentage, platelet lymphocyte ratio, and neutrophil-lymphocyte ratio were compared between groups with and without necrosis in terms of treatment.
RESULTS: The effectiveness of immature granulocyte percentage (IG%) and IG markers were statistically significant in predicting necrosis. The AUC was the highest for IG (0.820, 95% CI: 0.586-1), followed by IG% (0.820, 95% CI: 0.617-1). The optimal cut-off value for the IG was 0.65, with a sensitivity of 76.2% and specificity of 85.7% (P = 0.013). The optimal cut-off value for the IG% was 0.065, with a sensitivity of 85.7% and specificity of 71.4% (0.018).
CONCLUSION: IG% and IG count were found to be useful for predicting necrosis in patients with volvulus.
Training content was prepared in three stages according to the "resilience model in midwives". The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews.
NEW MATERIAL:A compound shown by formula I (R<1> is H or lower acyl; R<2> is H or lower alkyl; X is group shown by formula II-V). EXAMPLE:Ussurienin. USE:Having coronary vasodilating action, anti-choline action and anti-histamine action and useful as a treatment for hypertension. PREPARATION:A bulb of Fritillaria ussuriensisis ground and extracted with acetone-water mixed solvent (preferably 50:50 V/V %). The extracted solution is de-fatted with a nonpolar organic solvent such as hexane, treated by column chromatography using a porous carrier, an alkaloid component is adsorbed and eluted by using a mixed solution of a lower alcohol such as methanol and water through concentration gradient of the lower alcohol. Powder from fractions positive in alkaloid is hydrolyzed and then the aimed substance is isolated by gel column chromatography.
A protective and/or splint device, for example a distal radial splint device ( 200 ), comprises a protective and/or splint member ( 201 ) and a spacer member ( 13 ). The protective and/or splint member ( 201 ) comprises a composite protective and/or splint material and is formable at a forming temperature and is substantially rigid at ambient temperature. The material comprises a polycaprolactone and a ligno-cellulose additive material. The protective and/or splint member ( 201 ) comprises a mesh of elements ( 202 ), with a plurality of openings ( 203 ) through the protective and/or splint member ( 201 ). Away from the periphery of the splint member ( 201 ), the openings ( 203 ) are diamond-shaped. Two border elements ( 204 ) extend along the two sides of the periphery of the splint member ( 201 ). The three point bending strength to openness ratio of the member is greater than 0.1 and the unidirectional bending strength to openness ratio of the member is greater than 4. This results in a device ( 200 ) with sufficient strength, which is breathable with open surfaces, and the volume of material used is optimized. The strength of the member ( 201 ) parallel to the longitudinal direction of the arm is greater than the strength parallel too the circumferential direction. At the forming temperature the member ( 201 ) is stretchable. The member ( 201 ) is rounded between the outer surface of the member ( 201 ) and the edges around the openings ( 203 ).
Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
The invention discloses a recombined litopenaeus setiferus protein SF-P9, a preparation method thereof and an application thereof. Besides the invention also relates to coding of an amino acid sequence of the recombined litopenaeus setiferus protein SF-P9 and a DNA sequence corresponding to the amino acid sequence, a yeast recombination gene engineering bacterial strain Pichia pastoris X-33/ pPIC6alpha/Pen with a preservation code of CCTCC No: M209126, as well as the utilization of the engineering bacterial strain to express the recombined litopenaeus setiferus protein SF-P9. Moreover, the invention also discloses a litopenaeus setiferus protein F-P6, a preparation method and an application thereof. Besides, the coding of an amino acid sequence of the litopenaeus setiferus protein Pen6 and a DNA sequence corresponding to the amino acid sequence is also disclosed in the invention. The recombined litopenaeus setiferus protein SF-P9 has enterokinase sites. After the process of enterokinase cutting on the litopenaeus setiferus protein SF-P9, the litopenaeus setiferus protein F-P6 is obtained. The litopenaeus setiferus protein SF-P9 and the litopenaeus setiferus protein F-P6 have obvious biological activities of antibacterial infection, antimycotics infection, and anti-virus infection, as well as have an obvious effect of inhibiting tumor cell growth. Besides, the litopenaeus setiferus protein SF-P9 and the litopenaeus setiferus protein F-P6 can be applied to prepare medicaments for treating or preventing bacteria infection, fungi infection and virus infection and to prepare antitumor drugs.
The present invention relates to the discovery of the human survival motor-neuron gene or SMN gene which is a chromosome 5-SMA (Spinal Muscular Atrophy) determining gene. The present invention further relates to the nucleotide sequence encoding the SMN gene and corresponding amino acid sequence, a vector containing the gene encoding the SMN protein or a DNA sequence corresponding to the gene and transformant strains containing the SMN gene or a DNA sequence corresponding to the gene. The present invention also defines means for the detection of genomic abnormalities relating to motor neuron diseases at the level of the T-BCD541 gene or at the level of the C-BCD541 gene. The sequences of the invention are either DNA (especially genomic DNA or cDNA or synthetic DNA) or RNA. They can be used as probes for the detection of the T-BCD541 or C-BCD541 genes or as primers for the amplification of genomic DNA present in a biological sample. The invention also concerns cloning or expression vectors comprising a nucleotide sequence as defined above. Such vectors can be, for example, plasmids, cosmids, phages, YAC, pYAC, and the like. Preferably, such a vector has a motor neuron tropism. Especially for the purpose of defining means for gene therapy, it can be chosen among poliovirus vector, herpes virus, adenovirus, retrovirus vectors, synthetic vectors and the like.
BACKGROUND: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. PsA disease involves flares, which are associated with increased joint inflammation and tissue remodeling. There is a need for identifying biomarkers related to PsA disease activity and flares to improve the management of PsA patients and decrease flares. The tissue turnover imbalance that occurs during the inflammatory and fibro-proliferative processes during flares leads to an increased degradation and/or reorganization of the extracellular matrix (ECM), where increased proteolysis plays a key role. Hence, protease-mediated fragments of inflammatory and tissue-remodeling components could be used as markers reflecting flares in PsA patients.
METHODS: A broad panel of protease-mediated biomarkers reflecting inflammation and tissue remodeling was measured in serum and synovial fluid (SF) obtained from PsA patients experiencing flares (acutely swollen joint[s], PsA-flare). In serum, biomarker levels assessed in PsA-flare patients were compared to controls and in early-diagnosed PsA patients not experiencing flares (referred to as PsA without flare). Furthermore, the biomarker levels assessed in SF from PsA-flare patients were compared to the levels in SF of osteoarthritis (OA) patients.
RESULTS: In serum, levels of the PRO-C3 and C3M, reflecting formation and degradation of the interstitial matrix, were found significantly elevated in PsA-flare compared to controls and PsA without flare. The remodeling marker of the basement membrane, PRO-C4, was significantly elevated in PsA-flare compared to PsA without flare. The inflammation and immune cell activity related markers, CRPM, VICM, and CPa9-HNE were significantly elevated in PsA-flare patients compared to controls and PsA without flare. In addition, VICM (AUC = 0.71), CPa9-HNE (AUC = 0.89), CRPM (AUC = 0.76), and PRO-C3 (AUC = 0.86) showed good discriminatory performance for separating PsA-flare from PsA without flare. In SF, the macrophage activity marker, VICM, was significantly elevated whereas the type II collagen formation marker, PRO-C2, was significantly reduced in the PsA-flare compared to OA. The combination of five serum markers reflecting type III and IV collagen degradation (C3M and C4M, respectively), type III and VI collagen formation (PRO-C3 and PRO-C6, respectively), and neutrophil activity (CPa9-HNE) showed an excellent discriminatory performance (AUC = 0.98) for separating PsA-flare from PsA without flares.
CONCLUSIONS: The serum biomarker panel of C3M, C4M, PRO-C3, PRO-C6, and CPa9-HNE reflecting synovitis, enthesitis, and neutrophil activity may serve as novel tool for quantitatively monitoring flares in PsA patients.
The present invention generally relates to artemisinin/dihydroartemisinin (DHA) derivatives, and their use for therapy, in particular cancer therapy. These tumor-homing artemisinin derivatives (THAD) comprise three moieties: an artemisinin/DHA or a derivative thereof, a heptamethine carbocyanine dye (HMCD) residue, and a linker that conjugates the HMCD dye residue to the artemisinin residue. The THAD include compounds wherein the linker is linked to one or two DHA residue(s) via one or more ether bonds, and wherein the linker is linked to two DHA residues via two bonds independently selected from ester, carbamate and thiocarbamate. The THAD of the invention provide improved growth inhibition of cancer cells. The present invention also relates to improved methods of cancer therapy wherein a THAD is administered to a cancer patient. In embodiments, one or more THAD may be co-administered in a coordinated administration schedule. Advantages of the THAD and their use include, among others, improved dose-response and/or efficacy. The invention also relates to new dyes, their drug conjugates, and processes of making them.
After the root canal preparation was completed, the working length was checked with the master cone and periapical radiography. Root canal sealer was applied to the root canal walls using a master cone. HeatPlugger connected to the down-pack unit of the obturation system was adjusted to be 4 mm shorter than the working length. The master cone was cut 1 mm shorter than the working length with a heated plugger and applied to the root canal. Then, the heated plugger was advanced in the apical direction, and the apical region was obturated. Obturation was completed in 2 stages with gutta-percha in the gutta-percha cartridge connected to the remaining root canal cavity back-fill unit and heated to 200 °C. Heated gutta-percha was vertically condensed with HeatPlugger to 1 in the first stage and 2 in the second. The root canal obturation was completed by removing the gutta-percha 1 mm below the canal orifice.
PURPOSE:To enable early diagnosis of lung cancer, by applying a rabbit anti-serum to human lung flat epithelial cancer and an anti-lung cancer monoclonal antibody labelled with enzyme to a serum sample to assay the amount of antigen in the sample. CONSTITUTION:An anti-serum which was obtained by dosing a human lung flat epithelial cancer cell stock to a rabbit together with an adjuvant is distributed to a plate for EIA with 96 holes, which is allowed to stand at the room temperature for 2-4hr and then, washed by PBS. Bovine serum alubmin is added thereto and allowed to stand at the room temperature for 2hr. Then, a sample serum is applied to the plate, allowed to stand at the room temperature for 2hr and an anti-human lung cancer monoclonal antibody biotinated or labelled with peroxidase is fed thereto to be allowed to stand at the room temperature for 2-4hr. Thereafter, a reaction stopping agent is added thereto to stop the reaction. Colors formed at holes are measured with an absorbtiometer to find the amount of antigen in the serum sample. Thus, the amounts of antigens are compared between the normal person and lung cancer patients to obtain a reference diagnosis value.
This project will be divided into several methodological steps. First, we will establish an imaging protocol using high field MR systems (7T) to deliver high resolution data. The new T1/T2-star contrasts mechanisms observed in high field data will make possible the segmentation of the central structures, more specifically those deeply located in the brainstem, the pons and the mesencephalon that are involved in Parkinsonian syndromes. Second, we will characterize the cytarchitectony of the deep structures and the anatomical connectivity involved in the Parkinsonian syndromes using high angular resolution diffusion imaging (HARDI). The local information about the organization of the tissue coming from the HARDI data will be used to subdivide the deep structures into smaller nuclei. We will also use the HARDI data to infer the connectivity of these structures, employing probabilistic tractography algorithms more efficient to detect the smallest bundles. Such techniques have never been used for Parkinsonian syndrome, and may highlight structural differences inside deep nuclei that could not be observed when performing statistics on the entire structure. Third, preclinical studies will be performed in order to tackle the best spatial and angular resolutions and to build an atlas of the brainstem that will help understanding its structural organization. Clinical acquisitions will be done to acquire two databases of healthy volunteers and patients suffering from Parkinsons disease and progressive supranuclear palsy. Fourth, we will develop a statistical tool for isolating the biomarkers of the Parkinsonian syndrome and to create a diagnosis tool of the pathology, relying on robust bootstrapping techniques. The markers will stem from comparisons between populations using the various informations available. Expected results In this project, we will develop ultra high field techniques that will allow us to investigate the characteristics of the brainstem structures and of the central deep nuclei in normal subjects and in parkinsonian syndromes. The findings obtained with these image innovation techniques will help to overcome the present technical difficulties and limits of 1.5 and 3T MRI as some of the methods will be transferred to the routine machines and results will be compared to the images obtained on 3T MRI, in order to make new diagnosis tools available, in clinical research or clinical practice. The ultimate goal is to improve the accuracy of diagnosis of various parkinsonian syndromes at a early stage, to detect at a pre-clinical stage abnormalities that may reflect the underlying anatomical lesions, to improve the accuracy of neurosurgical targeting for deep brain stimulation, to detect imaging markers that may be useful biomarkers of the progression of the disease in neuroprotective therapy.
Background Deformity surgery is considered one of the most painful procedures patients can undergo in medicine today. Stringent protocols for pain management have done much to dramatically increase patient satisfaction, but the procedure still lags considerably behind advances in pain control when compared to other procedures such as total joint surgery. Specifically, it has been reported that over half of patients undergoing spine surgery report inadequate pain control the first 24 hours after surgery. Uncontrolled pain has been shown to correlate with prolonged hospital stays, delayed ambulation, poor functional outcomes, and increased risk for the development of chronic pain. Furthermore, the large amount of narcotics given to patients in an attempt to mitigate their pain postoperatively often leads to significant complications in their own right, such as ileus, mental status changes, and nausea. New modalities to treat postoperative pain, especially in the initial days following deformity correction, are needed.

Intrathecal (subarachnoid) injection of morphine has been used to treat severe pain since the 1970's. Its efficacy in treating postoperative pain has been well documented in various specialties including obstetrics, oncology, general surgery, and orthopedic surgery. Specific to spine surgery, intrathecal morphine is an attractive option given the access and visualization of the thecal sac in addition to the high demand of pain control required postoperatively. However, there remains no definitive consensus regarding the use of intrathecal morphine in spine surgery. Current literature is limited by few randomized trials, small sample sizes, heterogeneity of outcomes recorded, and an unclear association with complications. Additionally, there is a paucity of data dedicated to patients undergoing deformity correction. Accordingly, there is a need for high-quality trials to investigate the role of intrathecal morphine in adult spinal deformity surgery.

In this study, we hypothesized that the use of intrathecal morphine will significantly reduce post-operative pain after deformity surgery, reduce opioid utilization, decrease hospital stay, allow for earlier ambulation, increase patient satisfaction, and have comparable complications to traditional pain management strategies. This study aims to compare the effects of intrathecal morphine to traditional pain management strategies on post-operative recovery for deformity surgery.
AIM: Mesorectal extranodal tumor deposits (TDs) are identified in many rectal cancers. Their radiological features differ from metastatic lymph nodes, and they can be detected with magnetic resonance imaging (MRI). The purpose of this study was to determine the prevalence of rectal cancer TDs detected with MRI and their impact on overall (OS), cancer-specific (CSS), and disease-free survival (DFS) and the local recurrence rate.
METHOD: In this retrospective cohort study, we screened all 525 consecutive rectal cancer patients who underwent surgery during 2017-2018 in a tertiary center. Patients with synchronous metastases or who had not undergone MRI were excluded. We analyzed the OS, CSS, and DFS as well as local recurrences.
RESULTS: Of the 480 included patients, TDs were detected in the images of 81 (16.9 %). Extramural venous invasion (EMVI) and TDs were frequently found together (n = 50, 61.7 % of all cases with TDs). The presence of TDs alone [hazard ratio (HR) 1.66 (1.03-2.68)] or TDs and/or EMVI [HR 1.63 (1.01-2.62)] were risk factors for adverse DFS in multivariate Cox regression analysis. The OS and CSS rates were poorer among patients with TDs compared to those without, p = 0.009 and p < 0.001, respectively. TDs were also a risk factor for local recurrence in the univariate analysis.
CONCLUSIONS: TDs detected with imaging are a risk factor for impaired DFS and associated with impaired CSS and OS of rectal cancer patients and should be taken into consideration in clinical decision-making.
PURPOSE: In developed countries, endometrial cancer (EC) is the most prevalent gynecological cancer and its occurrence is associated with chronic inflammation. ATP5F1D is a subunit of ATP synthase (complex V), as well as the important component of mitochondrial electron transport chain (ETC). ETC play compelling roles in carcinogenesis. To date, little is known about the role of ATP5F1D in EC.
METHODS: ATP5F1D expression was identified in EC tissues and EC cell lines. We evaluated the influence of ATP5F1D on clinical features and prognosis based on TCGA database. The effects of ATP5F1D in EC malignant progression by applying loss-of-function assays in KLE and Ishikawa cell lines were detected by EdU, CCK-8, wound healing, Transwell, and flow cytometry assays. Additionally, electron microscope, LDH release, ELISA, mitochondrial ROS measurement, and Immunofluorescence were performed to demonstrate ATP5F1D can affect the pyroptosis of EC. To observe the anti-tumor effect on ATP5F1D silencing, we established an in vivo human endometrial tumor model using nude mice.
RESULTS: ATP5F1D expression was significantly upregulated in EC and was associated with favorable prognosis. ATP5F1D knockdown inhibited the proliferation, invasion, and migration of EC cells. Similarly, in nude mice, ATP5F1D knockdown suppressed the growth EC cells. Knocking down ATP5F1D lead to decrease the production of mitochondrial ROS (mtROS) and inhibited pyroptosis of EC cells.
CONCLUSION: Downregulation of ATP5F1D as a new therapeutic strategy that could mediate pyroptosis via suppressing mtROS/NLRP3/caspase-1/GSDMD pathway to inhibit EC progression.
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to dermatology, more specifically to methods of treating pyoinflammatory skin diseases, particularly furunculosis and acne. The method of treating the patients suffering pustular skin disorders, according to the invention, consists in the fact that the affected and surrounding skin areas are prepared with warm weak antiseptic, dried and further processed with an ointment prepared by thorough mixing on a water bath until smooth: zinc-salicylic paste, Lorinden C, gioxizone, streptocide liniment, synthomycin liniment and retinol acetate in the ratio of 3÷1÷1÷1÷0.8÷0.1 with skin treatment produced 2 times a day. The weak antiseptic is sodium bicarbonate or chamomile infusion at temperature 40-45°C. Besides, water bath temperature is to be 40-50°C, and the ointment is to be prepared is a glass or ceramic container. Face acne requires the affected area to be warmed with a vapour bath before finally applying the ointment. To prevent accidental wipe-out of ointment from the ointment treated skin, it is covered with the napkins attached to healthy skin. To enhance the effect of the ointment applications, the affected skin is exposed to UV lamp and/or sunlight for 10-30 minutes.EFFECT: method enables faster treatment and prevented the recurrent disease, and also ensures the prevention of side effects and provides outpatient treatment.6 cl, 7 dwg
PURPOSE: A cosmetic composition containing Lloydia triflora Bak extract is provided to suppress MMP-1 generation and malenogenesis and to ensure antioxidation. CONSTITUTION: A cosmetic composition for antioxidation contains Lloydia triflora Bak extract as an active ingredient. A cosmetic composition for anti-wrinkling contains Lloydia triflora Bak extract as an active ingredient. A cosmetic composition for skin whitening contains Lloydia triflora Bak extract as an active ingredient. A cosmetic composition for suppressing skin injury due to UV ray contains Lloydia triflora Bak extract as an active ingredient. The extract is contained in 0.001-30.0 weight% based on the total cosmetic composition. The extract is isolated by solvent extraction, supercritical extraction, sonication, or natural or microorganism fermentation.